14.2.2 Secondary endpoints

14.2.2.14-17 Evaluation of grading of bone marrow fibrosis and QOL

Table 14.2.2.15: Evaluation of grading of bone marrow fibrosis at 2 months, 4 months, 1 year and 3 years after Ruxolitinib continuous therapies - Full Analysis Population

Visit	Bone marrow fibrosis grading	N (%)
After 2 months of Ruxolitinib continuous therapy	MF-1	1 (7.1%)
	MF-2	1 (7.1%)
	MF-3	2 (14.3%)
	Missing	10 (71.4%)
After 4 months of Ruxolitinib continuous therapy	MF-3	3 (21.4%)
	Missing	11 (78.6%)
After 1 year of Ruxolitinib continuous therapy	MF-1	1 (7.1%)
	Missing	13 (92.9%)
After 3 years of Ruxolitinib continuous therapy	Missing	14 (100.0%)

Total N for Full Analysis Population allocated to ContRuxo arm = 14 .All percentage values are rounded to 1 decimal place. ContRuxo: Ruxolitinib continuous therapy.

Page 1 of 1